---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285250137.md"
description: "Arrowhead Pharma shares are trading lower. The company announced an exclusive worldwide license agreement with Madrigal Pharma for ARO-PNPLA3 as potential treatment for metabolic dysfunction-associated steatohepatitis."
datetime: "2026-05-05T18:29:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285250137.md)
  - [en](https://longbridge.com/en/news/285250137.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285250137.md)
---

# 

Arrowhead Pharma shares are trading lower. The company announced an exclusive worldwide license agreement with Madrigal Pharma for ARO-PNPLA3 as potential treatment for metabolic dysfunction-associated steatohepatitis.

### Related Stocks

- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)
- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock](https://longbridge.com/en/news/286489870.md)
- [Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near](https://longbridge.com/en/news/286388526.md)
- [Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR](https://longbridge.com/en/news/280430070.md)
- [Madrigal Pharmaceuticals Q4 revenue rises sharply on Rezdiffra sales](https://longbridge.com/en/news/276330392.md)